Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 15/20 | 0.73 |
| ▸ | CDK5 | Q00535 | 13/20 | 0.73 |
| ▸ | CDK5R1 | Q15078 | 13/20 | 0.73 |
| ▸ | CCNA2 | P20248 | 13/20 | 0.73 |
| ▸ | CCNA1 | P78396 | 13/20 | 0.73 |
| ▸ | DYRK1A | Q13627 | 11/20 | 0.73 |
| ▸ | CDK1 | P06493 | 3/20 | 0.57 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.56 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3298667 | 0.81 | CDK1 (0.63) | CDK2CDK5CDK5R1DYRK1ACDK1 | |
| SCHEMBL20549679 | 0.81 | CDK1 (0.58) | CDK2CDK5CDK5R1CCNA2CCNA1 | |
| SCHEMBL4478416 | 0.80 | CDK2 (0.74) | CDK2CDK5CDK5R1CCNA2CCNA1 | |
| SCHEMBL5749121 | 0.80 | CDK1 (0.70) | CDK2CDK5CDK5R1CCNA2CCNA1 | |
| SCHEMBL16714573 | 0.79 | EGFR (0.58) | CDK2CDK5CDK5R1CCNA2CCNA1 | |
| SCHEMBL6565678 | 0.76 | CDK5 (0.66) | CDK2CDK5CDK5R1CCNA2CCNA1 | |
| SCHEMBL5839686 | 0.76 | CDK5 (0.76) | CDK2CDK5CDK5R1CCNA2CCNA1 | |
| SCHEMBL1325062 | 0.76 | CDK5 (0.70) | CDK2CDK5CDK5R1CCNA2CCNA1 | |
| SCHEMBL6245433 | 0.76 | CDK5 (1.00) | CDK2CDK5CDK5R1CCNA2CCNA1 | |
| SCHEMBL6245437 | 0.76 | CDK5 (1.00) | CDK2CDK5CDK5R1CCNA2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612079-B2 | 2,6,9-substituted purine derivatives and their use in the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-11-03 | — | — | US | disclosed |
| EP-1399446-B1 | 2,6,9-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LTD (GB) | 2005-08-03 | — | — | EP | disclosed |
| US-20050009846-A1 | 2,6,9-Substituted purine derivatives and their use in the treatment of proliferative disorders | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2005-01-13 | — | — | US | disclosed |
| EP-1399446-A1 | 2,6,9-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2004-03-24 | — | — | EP | disclosed |
| WO-2003002565-A1 | 2,6,9-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE N THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009846-A1 | 2,6,9-Substituted purine derivatives and their use in the treatment of proliferative disorders | TYMP, PNP, IMPDH1 | CDK2 40/4885CDK5 83/4885CDK5R1 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.